Destiny Pharma Share Discussion Threads

[xcap1] 20/1/2024 14:25

Crikey ! Lol

[supracat] 19/1/2024 16:32

Think we r going to hold u to that Xcap!

[mam fach] 19/1/2024 16:31

RNS for Monday it is then Xcap1

[jeanesy] 19/1/2024 16:05

looks like seller still has the upper hand here atmo. Any rise being sold into

[xcap1] 19/1/2024 15:08

Be nice to think an RNS lands Monday morning

[supracat] 19/1/2024 13:57

Agreed. Can't believe we are marching through January and into Feb and still no deal and no dermal update either.....nor sporegen. Can only guess they are deep in the throes of a very detailed deal or a potential takeover of the XF platform or DP in its entirety, the latter being my guess.

[mam fach] 19/1/2024 12:10

Price holding up remarkably well .
Update on deals long overdue.
Let's have confirmation next week.
Stay safe.

[captain james t kirk] 19/1/2024 11:35

Apologies for the length of this as the article is behind a paywall but I have also posted the link as well.
XF-73 anti fungal targets Candida albicans, which as the article says is on the critical list of the WHO.



"Worldwide fungal deaths twice as high as previously thought, research shows
A new study suggests that fungal infections now account for around six per cent of all global deaths

Lilia Sebouai
19 January 2024 • 10:08am
Candida auris, which has a fatality rate between 30 and 72 per cent, is of particular concern.
Candida auris, which has a fatality rate between 30 and 72 per cent, is of particular concern. CREDIT: KATERYNA KON/Science Photo Library RF
Around four million people are dying every year from fungal infections, new research indicates – nearly double the previous global estimate.

The study, published in the Lancet Infectious Diseases journal, says that more than 6.55 million people annually are affected by invasive fungal infections. These lead to more than 3.75 million deaths, of which 2.55 million are directly attributable to fungal disease.

According to the estimate, this means fungal infections account for around six per cent of all global deaths, killing six times more people than malaria, and almost three times as many as tuberculosis.

There are millions of different fungal species across the planet, which humans are regularly exposed to in everyday life. The vast majority of people have immunity to these infections and do not develop disease.

However, such pathogens can be deadly for those with weakened immune systems, such as cancer and HIV patients, who make up a large number of the people dying every year from fungal infections.

The revised global death toll is based on an extensive review of data taken from hundreds of studies published between 2010 and 2023, along with 85 papers on global disease burdens.

It is higher than previous calculations, which suggested fungal infections kill up to two million people each year.

This estimate failed to take into full consideration those cases of fungal disease that go undiagnosed and untreated because of limited access to diagnostics, the new research said.

Indeed, testing of fungal cultures only identifies about a third of people who actually have a fungal infection, according to Prof David Denning, the chief investigator of the study.


The research also said that deaths among patients with weakened immune systems can be mistakenly attributed to their long-term condition, such as cancer or chronic obstructive pulmonary disease, as opposed to the real cause of their passing: a fungal infection.

However, Prof Denning cautioned that the new estimates were “necessarily crude”. He added: “Many gaps and uncertainties remain.”

Tihana Bicanic, Professor of Infectious Diseases and Mycology at St George’s, University of London, said that she wasn’t surprised by the large number of people killed every year by fungal infections, which have been “historically neglected, compared to the focus on bacterial infections and antibiotics”. Prof Bicanic was not involved in the study.

In 2022, the World Health Organisation (WHO) unveiled a list of priority fungal pathogens, including 19 deemed to pose a significant threat to public health. Of these, four were identified as being of “critical” priority.

These included Aspergillus fumigatus and Candida albicans – the two most common fungal pathogens globally – as well as Cryptococcus neoformans, which is a particular threat to those with weakened immune systems and is a leading cause of death in people living with HIV.

Aspergillus fumigatus mainly affects the lungs and is responsible for 2.1 million fungal infections annually, according to the study. A further 1.5 million people are estimated to experience a Candida bloodstream infection each year.

Rebecca Drummond, Associate Professor at the Institute of Microbiology & Infection in Birmingham, called the study “important” as it helps to outline the most deadly fungal diseases.


Prof Bicanic said that the report’s findings will hopefully improve awareness of the threats posed by fungal infections and promote the development of diagnostic capabilities.

“We need to direct attention in terms of research and development efforts,” she said.

Separately, recent reports have warned that climate change is accelerating the spread of dangerous fungal infections.

Many of the fungi that exist in nature are not well suited to humans due to our high body temperature, but global warming is driving adaptations in these pathogens, enabling them to better infect human hosts.

Prof Bicanic meanwhile warned that the overuse of antifungals – which can be used by hospitals in a preventative capacity, such as in the case of bone marrow transplants, and to treat skin infections like athlete’s foot – could also be fuelling the rise of antifungal-resistant infections.

“Unlike antibiotics, we have about three classes of antifungals that we widely use in patients,” she said.

“All this usage is essentially putting pressure on the fungi, allowing them to adapt and become resistant and that is in fact what’s happening now.”

[john henry] 17/1/2024 14:47

Large seller still dumping stock into any rise

[captain james t kirk] 17/1/2024 13:36

I mentioned the other day the BBC article about the Roche work on a drug to counter antibiotic resistance to Acinetobacter baumannii (Crab) bacterium.
As we are awaiting imminent news, I re visited the Destiny Pharma site for the XF-73 dermal product. As we should all be aware XF-73 is designed primarily for combatting resistance to Staphyloccucus aureus, but in the final paragraph of this excerpt, it also potentially targets baumannii :

"There are two XF-73 dermal programmes currently in development. One is being run by our China partner and shareholder – China Medical Systems Holdings Limited (CMS) – focused on superficial skin infections and the other is an in-house programme looking at the use of XF-73 for the prevention and treatment of serious infections associated with burns and open wounds such as diabetic foot ulcers (DFUs). The latter programme is in collaboration with the US government’s National Institute of Allergy and Infectious Diseases (NIAID).

Phase 1 skin irritation studies completed in 2019 were the first data supporting the use of XF-73 on damaged skin. Following these positive data, the Company is now performing further work on formulation development, in vivo models and Phase 1 study planning (potentially in patients, Phase 2a, with the target infections) with the aim of building a Phase 2/3 ready package.

The company has a strong Phase 1 clinical, pre-clinical, in vitro and in vivo infection model data set which demonstrates the efficacy of topically applied XF-73 against Gram positive and Gram negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and Acinetobacter baumannii. In some cases, unformulated XF drugs have been shown to be as active as existing, marketed antibiotics."

No need to elaborate on the potential significance of this statement.

[xcap1] 17/1/2024 13:07

Personally I think days this week or next week

[xcap1] 17/1/2024 13:07

Let's just agree on , it's coming soon lol

[xcap1] 17/1/2024 13:06

But then the question becomes what do we understand as 'very soon' lol

[xcap1] 17/1/2024 13:05

Dictionary meaning = very soon , so you could be right :))

[xcap1] 17/1/2024 13:04

Semantic ... a few weeks imo would have read 'shortly' or to cover himself 'within Q1'

[supracat] 17/1/2024 12:59

My own view of 'imminent, was within a few weeks. I'd have expected something by end of next week if not this week.

[mam fach] 17/1/2024 12:54

Agree. My thoughts exactly could easily double on news.

[supracat] 17/1/2024 12:53

Agree whispa. A good deal for XF nasal will see the shares triple to over 200p share.

[wh1spa] 17/1/2024 12:44

I still maintain that any big news at start of play and this will open at £2

[mam fach] 17/1/2024 12:41

If we can break through 80p barrier it will be up, up & away.
News can't be far away.
After all new CEO been here since September.
He wouldn't have accepted post unless he was fairly sure of success.
Hospitals desperate for products to combat infections.
GLA

[xcap1] 17/1/2024 12:28

The market seems to pricing in an update very soon I think

[xcap1] 17/1/2024 12:27

I did. Yes agree they need to be a bit more careful with language. I think we would all agree 'imminent' would indicate within the next few days ...I think we should expect/hope for the clinical results update in the next few days

[arab3] 17/1/2024 12:17

Who promised an update ?

[marvelman] 17/1/2024 09:32

Yes, share price seems quite resilient around this area. Surely must be getting very close to the promised update